MedTrace Logo

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

NCT01353963 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2016-01-18

Study results available
· View outcomes & findings →

Summary

This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.

Conditions

Interventions

DRUG

desvenlafaxine succinate

50 mg tablet once daily

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01353963 on ClinicalTrials.gov